Important: Deadline is 12.00 noon on 01 September 2020

You will find all webinars of this series in this overview

Background

In June 2018 EU authorities were notified that a Chinese API manufacturer has detected the presence of N-nitrosodimethylamine, NDMA, in batches of Valsartan. Meanwhile different Nitrosamines (NDMA, NDEA and others) were detected in several drug products containing Sartan derivatives as an API. NDMA is a genotoxic and carcinogenic agent in animals and is classified as a Class 2A carcinogen to humans. Therefore Marketing Authorisation Holders are requested to evaluate the risk of the presence of Nitrosamine impurities in human medicinal products containing chemically synthesised APIs and to take immediate steps to avoid nitrosamines in human medicines. As a consequence in case of any contamination with mutagenic impurities Marketing Authorisation Holders have to file a variation application. All regulatory activities with regard to such cases have to be completed within a 3 years period.

Target Group

The webinar addresses all personnel involved in development of drug substances and drug products from scientific staff to laboratory heads involved in R&D. The needs of Laboratory Managers, Supervisors and Analysts in pharmaceutical quality assurance and quality control departments will also be covered. This event will also address regulatory requirements and hence is applicable to people working in the regulatory affairs area.

Technical Requirements

For our webinars, we use Cisco WebEx, one of the leading suppliers of online meetings.

At http://www.webex.com/test-meeting.html you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Programme

This webinar will provide an update of the expectations of regulatory authorities with respect to mutagenic impurities with focus on Nitrosamines.

The following topics will be addressed:

Overview ICH M7 principles
Nitrosamines – the Valsartan case
Limits, interim limits and acceptable intakes
Deadlines for submitting risk assessments
Variation procedures

A representative of a Regulatory Authority will explain the assessors approach in the assessment of dossiers in particular with respect to the Impurities section.

This event is currently unavailable. Visit the full overview for live events and recordings, or contact our team directly via the contact form.

* also payable by credit card

Recording/ Additional dates on-site
not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0
E-Mail: info@gmp-compliance.org

Go back

Testimonials about our courses and conferences

"Great material and speakers" and "Great speakers a lot of experience and sharing"

Felipe Gonzalez, Mucos Emulsionsgesellschaft mbH
Live Online Training - Granulation & Tableting, September 2024

“I found the course eye opening and very well organized.”

Jozsef Maklary, Veolia Industries Austria GmbH
The GMP-Compliance Manager, October 2025

"I am so grateful for having attended this course. Great job from all, and very profitable. Thanks!”

Alba Aranda Cuesta, Kern Pharma
KPIs and Quality Metrics, Berlin, Germany, April 2025

"The lectures were very informative, interesting and entertaining."

Albert Godoy Hernández, Company synaffix
Live Online Training - GMP Auditor Practice, October 2024

"Really useful training which I will use in my daily work."

Regina Mommaerts, Galapagos NV
Live Online Training - GMP Auditor Practice, October 2024

"Wonderful format of the sessions: Good range of participations and experience in the team. Would love to attend another one soon."

Roopasi Mathi, Wacker Biotech B.V.
Live Online Training - GMP Auditor Practice, October 2024

"Very good balance between general and detailed information"

Dr Ralf Albrecht, Tillotts Pharma AG
Live Online Training - Granulation & Tableting
September 2024

"Nice presentations: easy understanding, quite visual"

Susana Manrique, Boehringer Ingelheim España, S.A,
Live Online Training - Granulation & Tableting, September 2024

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023

“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024

“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024

“Both, organizers and lecturers were very friendly, open for discussions and extremely constructive. The course was a valuable experience for me.”

Maria Dimitrova, NKN Law Firm
Pharmaceutical Contracts: GMP and Legal Compliance, March 2025

More testimonials

10% Early-Bird Discount until 30 June 2026

Book by 30 June 2026 and get 10% early-bird discount

Here’s how it works:

Select the event of interest
Book by 30 June 2026
Enter the code “SAVE10” during the booking process

The discount will be automatically deducted from the event fee.

*This offer does not apply to recordings and conferences with their own early bird discount (PharmaLab, QP Forum, API Conference).

Webinar Series on Impurities: Mutagenic Impurities with Focus on Nitrosamines - What do Regulatory Authorities Expect

Background

Target Group

Technical Requirements

Programme